Saturday, December, 14, 2019 05:40:14

Esperion puts forth the pooled analyses from phase 3 studies

The pharmaceutical company, Esperion Therapeutics, reportedly announced its four Phase 3 studies of the bempedoic acid at the American Heart Association Scientific Sessions in Philadelphia. The acid, as per credible sources, is being manufactured as a convenient, once-daily, oral therapy for the elevated low-density lipoprotein …